|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reductions and clinical benefit in patients with PV have not been extensively evaluated in a randomized trial.
|
28456851 |
2017 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Risk factors for vascular complications prior to diagnosis were lower hemoglobin in PV, and the presence of JAK2 V617F mutation, higher age, and leukocytosis in ET.
|
28251679 |
2017 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Emerging risk factors may include leukocytosis and presence of the JAK2 V617F mutation or an increase in its allelic burden.
|
23264112 |
2013 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The implementation of laboratory parameters such as leukocytosis and/or the JAK2 V617F mutation into a scoring system may be of interest.
|
23601811 |
2013 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Correlations are emerging between leukocytosis, JAK2(V617F) mutation, BM fibrosis, and different outcomes of PV, which need to be confirmed in prospective studies.
|
22611155 |
2012 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study is the largest hitherto carried out in this setting and shows that the rate of major CV events in PMF is comparable with that reported in essential thrombocythemia, and it is increased in aged patients and those with JAK2 V617F mutation and leukocytosis.
|
19965680 |
2010 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
|
20631743 |
2010 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Treating low-risk essential thrombocythemia and polycythemia vera patients presenting with leukocytosis or JAK2 V617F mutation in order to prevent thrombosis deserves a prospective validation.
|
19468275 |
2009 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that the extent of JAK2(V617F) CD34(+) cell clonal dominance is associated with disease phenotype within the MPD and, in PV, is associated with extramedullary disease, leukocytosis, and disease duration.
|
18723264 |
2008 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results showed that (1) an increased leukocyte count at diagnosis was associated with thrombosis during follow-up ("baseline analysis," relative risk [RR] 2.3, 95% confidence interval [CI] 1.4-3.9, P = .001); (2) hydroxyurea (HU) lowered leukocytosis and reduced the strength of the association between leukocytosis and thrombosis ("time-dependent analysis," RR 1.6, 95% CI 0.9-2.0, not significant [NS]); (3) the association of leukocytosis and thrombosis was more evident in untreated low-risk patients (RR 2.7, 95% CI 1.2-6.4, P = .01) compared with HU-treated high-risk patients (RR 1.6, 95% CI 0.8-3.2, NS); and (4) the presence of JAK2 V617F was not identified as a risk factor for thrombosis during follow-up despite a significant association between the mutation and leukocytosis.
|
17110452 |
2007 |
|
rs77375493
|
|
Leukocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
JAK2 V617F also induced leukocytosis and neutrophilia that was much more prominent in Balb/c mice than in B6.
|
17183644 |
2006 |